Heart failure (HF) remains a major cause of mortality, morbidity, and poor quality of life. It is
an area of active research. This article is aimed to give an update on recent advances in all …

Research about heart failure (HF) has made major progress in the last years. We give here
an update on the most recent findings. Landmark trials have established new treatments for …

2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart
Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection …

Aims To assess tolerability and optimal time point for initiation of sacubitril/valsartan in
patients stabilised after acute heart failure (AHF). Methods and results TRANSITION was a …

Foundational therapy for heart failure and a reduced ejection fraction consists of a
combination of an angiotensin receptor–neprilysin inhibitor, a beta‐blocker, a …

Abstract The Korean Society of Heart Failure (KSHF) guidelines aim to provide physicians
with evidence-based recommendations for the management of patients with heart failure …

Low blood pressure is common in patients with heart failure and reduced ejection fraction
(HFrEF). While spontaneous hypotension predicts risk in HFrEF, there is only limited …

Among the three natriuretic peptides, atrial/A-type natriuretic peptide (ANP) and brain/B-type
natriuretic peptide (BNP) are primarily produced by, and secreted from, heart tissue. They …

Aim Patients with heart failure with reduced ejection fraction and low systolic blood pressure
(SBP) have high mortality, hospitalizations, and poorly tolerate evidence-based medical …

The 2021 Update to the 2017 American College of Cardiology (ACC) Expert Consensus
Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues …